Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2017 · 10-Q
Revenue$100.80M$100.80M+10.5% vs Q2 2016 Net Income$4.62M$4.62MN/M vs Q2 2016 EPS Diluted$0.11$0.11N/M vs Q2 2016 Gross Profit$8,500,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$54,002,000N/M Free Cash Flowderived$44,701,000N/M Margins · derivedGross margin8.4%+10.7 pt vs Q2 2016
Operating margin8.5%+10.7 pt vs Q2 2016
Net margin4.6%+16.6 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 4, 2017 · 35 d after period end